A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS PF-06747143, ADMINISTERED AS SINGLE AGENT OR IN COMBINATION WITH STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
Latest Information Update: 05 Nov 2021
At a glance
- Drugs PF 6747143 (Primary) ; Azacitidine; Azacitidine; Cytarabine; Daunorubicin; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 28 Nov 2017 Status changed from recruiting to discontinued.
- 28 Sep 2017 Planned End Date changed from 11 Feb 2020 to 1 May 2020.
- 28 Sep 2017 Planned primary completion date changed from 11 Feb 2020 to 1 May 2020.